Q3 2025 Holdings
Filed 2025-11-13 | 96 holdings | $1.1B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Verona Pharma PLC(VRNA) | SPONSORED ADS | 925050106 | $66.7M | 625,000 | 5.8% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $64.8M | 450,000 | 5.6% |
| Spdr S&P 500 ETF TR(SPY) | TR UNIT | 78462F103 | $56.3M | 84,490 | 4.9% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $56.2M | 1,400,000 | 4.9% |
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $52.7M | 115,000 | 4.6% |
| Apogee Therapeutics Inc(APGE) | COM | 03770N101 | $46.6M | 1,173,426 | 4.1% |
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $41.1M | 500,000 | 3.6% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $37.5M | 1,250,000 | 3.3% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $33.2M | 384,417 | 2.9% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $30.6M | 360,000 | 2.7% |
| Insmed Inc(INSM)Call | COM PAR $.01 | 457669307 | $29.5M | 205,000 | 2.6% |
| Mineralys Therapeutics Inc(MLYS) | COM | 603170101 | $28.4M | 750,000 | 2.5% |
| Teva Pharmaceutical Inds LTD(TEVA) | SPONSORED ADS | 881624209 | $28.3M | 1,400,000 | 2.5% |
| Merus N V | COM | N5749R100 | $26.9M | 285,769 | 2.3% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $26.8M | 1,107,162 | 2.3% |
| Lexeo Therapeutics Inc(LXEO) | COM | 52886X107 | $25.7M | 3,870,527 | 2.2% |
| Trevi Therapeutics Inc(TRVI) | COM | 89532M101 | $25.6M | 2,800,000 | 2.2% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $23.8M | 1,419,299 | 2.1% |
| Rezolute Inc(RZLT) | COM NEW | 76200L309 | $19.7M | 2,100,000 | 1.7% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $19.2M | 350,000 | 1.7% |
| Oruka Therapeutics Inc(ORKA) | COM | 687604108 | $18.4M | 959,180 | 1.6% |
| Uniqure NV(QURE) | SHS | N90064101 | $17.5M | 300,000 | 1.5% |
| Wave Life Sciences LTD(WVE) | SHS | Y95308105 | $15.4M | 2,100,000 | 1.3% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $14.7M | 220,600 | 1.3% |
| Exelixis Inc(EXEL)Put | COM | 30161Q104 | $14.5M | 350,000 | 1.3% |
| Soleno Therapeutics Inc(SLNO) | COM | 834203309 | $13.5M | 200,000 | 1.2% |
| Avalo Therapeutics Inc(AVTX) | COM NEW | 05338F306 | $12.8M | 1,006,217 | 1.1% |
| Establishment Labs Hldgs Inc(ESTA) | COM | G31249108 | $12.7M | 310,000 | 1.1% |
| Karyopharm Therapeutics Inc | NOTE 3.000%10/1 | 48576UAA4 | $12.5M | $15,250,000 | 1.1% |
| Ventyx Biosciences Inc(VTYX) | COM | 92332V107 | $12.2M | 3,924,415 | 1.1% |
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $12.1M | 800,000 | 1.1% |
| Travere Therapeutics Inc(TVTX) | COM | 89422G107 | $12.0M | 500,000 | 1.0% |
| Dianthus Therapeutics Inc(DNTH) | COM | 252828108 | $10.3M | 262,100 | 0.9% |
| Taysha Gene Therapies Inc(TSHA) | COM SHS | 877619106 | $9.8M | 3,000,000 | 0.9% |
| Erasca Inc(ERAS) | COM | 29479A108 | $9.3M | 4,285,787 | 0.8% |
| Nurix Therapeutics Inc(NRIX) | COM | 67080M103 | $8.9M | 967,620 | 0.8% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $8.8M | 303,330 | 0.8% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $8.2M | 400,000 | 0.7% |
| Travere Therapeutics Inc | NOTE 2.250% 3/0 | 89422GAA5 | $7.9M | $7,000,000 | 0.7% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $7.8M | 275,000 | 0.7% |
| Celldex Therapeutics Inc New(CLDX) | COM NEW | 15117B202 | $7.8M | 300,000 | 0.7% |
| Proqr Thrapeutics N V | SHS EURO | N71542109 | $7.7M | 3,600,000 | 0.7% |
| Tarsus Pharmaceuticals Inc(TARS) | COM | 87650L103 | $7.4M | 125,000 | 0.6% |
| Summit Therapeutics Inc(SMMT)Put | COM | 86627T108 | $7.2M | 350,000 | 0.6% |
| Akebia Therapeutics Inc(AKBA) | COM | 00972D105 | $6.7M | 2,450,000 | 0.6% |
| Monopar Therapeutics Inc(MNPR) | COM NEW | 61023L207 | $6.5M | 79,483 | 0.6% |
| Exelixis Inc(EXEL)Call | COM | 30161Q104 | $6.2M | 150,000 | 0.5% |
| Zura BIO LTD(ZURA) | CLASS A ORD SHS | G9TY5A101 | $5.5M | 1,274,351 | 0.5% |
| Viridian Therapeutics Inc(VRDN) | COM | 92790C104 | $5.4M | 250,000 | 0.5% |
| Savara Inc(SVRA) | COM | 805111101 | $5.4M | 1,500,000 | 0.5% |